Poly(lactic acid) nanofibers containing phosphorylcholine grafts for transdermal drug delivery systems
DOXORUBICIN
Paclitaxel
MATERIALS SCIENCE, MULTIDISCIPLINARY
02 engineering and technology
PACLITAXEL
MATERIALS SCIENCE
UV-Grafting
Metaller ve Alaşımlar
Materials Chemistry
NANOPARTICLES
General Materials Science
MALZEME BİLİMİ, ÇOKDİSİPLİNLİ
Engineering, Computing & Technology (ENG)
RELEASE
Malzeme Kimyası
Electrospinning
Metals and Alloys
PROLIFERATION
Mühendislik, Bilişim ve Teknoloji (ENG)
Drug release
COPOLYMER
3. Good health
Fizik Bilimleri
PEGYLATED LIPOSOMES
Cancer treatment
Physical Sciences
Genel Malzeme Bilimi
Engineering and Technology
Mühendislik ve Teknoloji
0210 nano-technology
CELL-ADHESION
Malzeme Bilimi
ACCELERATED BLOOD CLEARANCE
DOI:
10.1016/j.mtsust.2022.100132
Publication Date:
2022-03-29T01:01:36Z
AUTHORS (5)
ABSTRACT
The continuous and prolonged releases of chemotherapeutic drugs are required for successful treatment in cancer treatment. The project focused on a new material design to meet this requirement. We developed a constant and sustained release system and investigated the release profiles of Paclitaxel (PTX). Polylactic acid (PLA) nanofiber surface was grafted with poly (methacryloyloxyethyl phosphorylcholine) (PMPC) by the UV-induced grafting method. The morphological structure of the PLA nanofibers did not change with an increase in the MPC content. PMPC blocks contribute to the solubility of PTX, which shows low resolution. When the amount of MPC is 5%, the PTX loading efficiency increased two times compared with PLA nanofiber. The nanofiber mats exhibited an initial fast release during the first 3 h. Endothelial cells were cultured on nanofiber mats to investigate whether this material was toxic or not. The mats showed good biocompatibility with HUVEC. Thus, it was confirmed that nanofiber mats would not be toxic when releasing drugs during in vivo use. We think that PMPC facilitates the pass of drugs through the lipid-rich biological membrane and so anticancer drugs can be delivered to direct tumor sites. (C) 2022 Elsevier Ltd. All rights reserved.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (48)
CITATIONS (7)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....